Cyclo Therapeutics Inc. (CTDH)
| Market Cap | 14.62M |
| Revenue (ttm) | 985,153 |
| Net Income (ttm) | -8.90M |
| Shares Out | 151.95M |
| EPS (ttm) | -0.06 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | Dec 11, 2021 |
| Last Price | $4.19 |
| Previous Close | $4.20 |
| Change ($) | -0.01 |
| Change (%) | -0.24% |
| Day's Open | 4.17 |
| Day's Range | 4.00 - 4.24 |
| Day's Volume | 93,402 |
| 52-Week Range | 3.55 - 34.99 |
News
There are no news available yet.
About CTDH
Cyclo Therapeutics, a biotechnology company, develops cyclodextrin-based products for the treatment of diseases. Its lead drug candidate is Trappsol Cyclo, an orphan drug for the treatment of Niemann-Pick Type C disease. The company also sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. It has a collaboration with the Chattanooga Center for Neurologic Research. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo ... [Read more...]
| Industry Biotechnology | Founded 1990 |
| CEO N. Scott Fine | Employees 5 |
| Stock Exchange OTCMKTS | Ticker Symbol CTDH |
Financial Performance
In 2019, CTDH's revenue was $1.01 million, a decrease of -0.42% compared to the previous year's $1.01 million. Losses were -$7.53 million, 77.0% more than in 2018.